CASC3 and ovarian cancer: Indeed, a recent study found that PARPi and BTZ combination treatment at a different concentration ratio than the one used here was more effective than single agent treatments in the chemosensitive ovarian cancer cell line OV2008 [66]; and another study demonstrated the effectiveness of BTZ treatment in PARPi-resistant cells [47].